BioCentury | Mar 24, 2021
Deals

March 23 Quick Takes: Moulder’s Zenas launches; plus PhoreMost, 1910 Genetics, XyloCor and Catalent

...by Quan Capital, WuXi Biologics Healthcare Ventures and Wellington Management. It is Tellus’ sixth portfolio company.PhoreMost...
...participated in the B round along with existing investors Parkwalk Advisors, Morningside Ventures and Jonathan Milner. PhoreMost...
...DNA cell and gene therapy CDMO based in Gosselies, Belgium.TARGETSPLK1 (STPK13) - Polo-like kinase 1 BC Staff PhoreMost Ltd. XyloCor...
BioCentury | Aug 1, 2019
Emerging Company Profile

NeoPhore: Driving neoantigen production via DNA mismatch repair

...inside patient cancers,” CEO Jeff Roix told BioCentury. NeoPhore spun out of U.K. cancer company PhoreMost Ltd....
...Hopkins University, Baltimore, Md. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Nouscom AG, Basel, Switzerland PhoreMost Ltd....
...PDCD1; CD279) - Programmed cell death 1 Mary Romeo, Assistant Editor Grey Wolf Therapeutics Johns Hopkins University NeoPhore Ltd. Nouscom AG PhoreMost Ltd. University...
BioCentury | Apr 12, 2018
Company News

Management tracks: Verona, Medigene, NeoPhore

...immuno-oncology company NeoPhore Ltd. (Cambridge, U.K.) hired Jeffrey Roix as CEO. He was COO at PhoreMost Ltd....
BioCentury | Nov 17, 2017
Company News

Sixth Element, PhoreMost spin out immuno-oncology newco

...million ($4 million) in newly created NeoPhore Ltd. (Cambridge, U.K.), a spinout from cancer company PhoreMost Ltd....
...the first asset-centric spinout of PhoreMost, will aim to build on discoveries already made by PhoreMost...
...Pioneer Fund. NeoPhore Ltd., Cambridge, U.K. PhoreMost Ltd., Cambridge, U.K. Business: Cancer Allison Johnson Cancer Research Technology Pioneer Fund PhoreMost Ltd. NeoPhore...
BioCentury | Oct 17, 2016
Company News

PhoreMost, University of Cambridge deal

...neurodegenerative diseases. The collaboration will use the university’s autophagy models with PhoreMost’s Siteseeker discovery technology. PhoreMost’s...
...into small molecule therapeutics. Cambridge referred inquiries to PhoreMost, which declined to disclose financial terms. PhoreMost Ltd....
BioCentury | Jul 21, 2016
Strategy

Brexit of brains

...the movement of qualified scientific staff is very low," said Nicholson. Chris Torrance, CEO of PhoreMost Ltd....
...King's Health Partners, London, U.K. MedCity Ltd., London, U.K. Medical Research Council (MRC), London, U.K. PhoreMost Ltd....
BioCentury | Jul 21, 2016
Emerging Company Profile

Drugging the undruggable

...targets, many of which go nowhere. By operating at the protein level to disrupt function, PhoreMost Ltd....
...isolated from the cells along with its bound target, which is identified by mass spectrometry. PhoreMost's...
...Cambridge, Cambridge, U.K. Targets and Compounds KRAS - K-Ras Sidebars PhoreMost Ltd., Cambridge, U.K. Corporate Profile PhoreMost Ltd....
BioCentury | Mar 21, 2016
Company News

PhoreMost, Wistar deal

...oncology and immunology. PhoreMost said the deal will also include aging. The partners will use PhoreMost’s...
...and Wistar’s high throughput phenotypic assay. Wistar will be responsible for mode of action studies. PhoreMost’s...
...then converts the information into small molecule therapeutics. The companies declined to disclose financial terms. PhoreMost Ltd....
BioCentury | May 4, 2015
Company News

Phylogica, PhoreMost deal

...Phylogica granted PhoreMost non-exclusive, worldwide rights to use undisclosed Phylomer libraries to screen cancer targets and...
...stake in PhoreMost. The companies declined to provide further terms. Phylogica Ltd. (ASX:PYC;Xetra:PH7), Subiaco, Australia PhoreMost Ltd....
BioCentury | Apr 13, 2015
Financial News

PhoreMost completes venture financing

PhoreMost Ltd. , Cambridge, U.K. Business: Cancer Date completed: 2015-04-07 Type: Venture financing Raised: L2.5 million ($3.7 million) Investors: Cambridge Angels; Amadeus Capital Partners; o2h Ventures; Cambridge Enterprise; company management WIR Staff...
Items per page:
1 - 10 of 10
BioCentury | Mar 24, 2021
Deals

March 23 Quick Takes: Moulder’s Zenas launches; plus PhoreMost, 1910 Genetics, XyloCor and Catalent

...by Quan Capital, WuXi Biologics Healthcare Ventures and Wellington Management. It is Tellus’ sixth portfolio company.PhoreMost...
...participated in the B round along with existing investors Parkwalk Advisors, Morningside Ventures and Jonathan Milner. PhoreMost...
...DNA cell and gene therapy CDMO based in Gosselies, Belgium.TARGETSPLK1 (STPK13) - Polo-like kinase 1 BC Staff PhoreMost Ltd. XyloCor...
BioCentury | Aug 1, 2019
Emerging Company Profile

NeoPhore: Driving neoantigen production via DNA mismatch repair

...inside patient cancers,” CEO Jeff Roix told BioCentury. NeoPhore spun out of U.K. cancer company PhoreMost Ltd....
...Hopkins University, Baltimore, Md. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Nouscom AG, Basel, Switzerland PhoreMost Ltd....
...PDCD1; CD279) - Programmed cell death 1 Mary Romeo, Assistant Editor Grey Wolf Therapeutics Johns Hopkins University NeoPhore Ltd. Nouscom AG PhoreMost Ltd. University...
BioCentury | Apr 12, 2018
Company News

Management tracks: Verona, Medigene, NeoPhore

...immuno-oncology company NeoPhore Ltd. (Cambridge, U.K.) hired Jeffrey Roix as CEO. He was COO at PhoreMost Ltd....
BioCentury | Nov 17, 2017
Company News

Sixth Element, PhoreMost spin out immuno-oncology newco

...million ($4 million) in newly created NeoPhore Ltd. (Cambridge, U.K.), a spinout from cancer company PhoreMost Ltd....
...the first asset-centric spinout of PhoreMost, will aim to build on discoveries already made by PhoreMost...
...Pioneer Fund. NeoPhore Ltd., Cambridge, U.K. PhoreMost Ltd., Cambridge, U.K. Business: Cancer Allison Johnson Cancer Research Technology Pioneer Fund PhoreMost Ltd. NeoPhore...
BioCentury | Oct 17, 2016
Company News

PhoreMost, University of Cambridge deal

...neurodegenerative diseases. The collaboration will use the university’s autophagy models with PhoreMost’s Siteseeker discovery technology. PhoreMost’s...
...into small molecule therapeutics. Cambridge referred inquiries to PhoreMost, which declined to disclose financial terms. PhoreMost Ltd....
BioCentury | Jul 21, 2016
Strategy

Brexit of brains

...the movement of qualified scientific staff is very low," said Nicholson. Chris Torrance, CEO of PhoreMost Ltd....
...King's Health Partners, London, U.K. MedCity Ltd., London, U.K. Medical Research Council (MRC), London, U.K. PhoreMost Ltd....
BioCentury | Jul 21, 2016
Emerging Company Profile

Drugging the undruggable

...targets, many of which go nowhere. By operating at the protein level to disrupt function, PhoreMost Ltd....
...isolated from the cells along with its bound target, which is identified by mass spectrometry. PhoreMost's...
...Cambridge, Cambridge, U.K. Targets and Compounds KRAS - K-Ras Sidebars PhoreMost Ltd., Cambridge, U.K. Corporate Profile PhoreMost Ltd....
BioCentury | Mar 21, 2016
Company News

PhoreMost, Wistar deal

...oncology and immunology. PhoreMost said the deal will also include aging. The partners will use PhoreMost’s...
...and Wistar’s high throughput phenotypic assay. Wistar will be responsible for mode of action studies. PhoreMost’s...
...then converts the information into small molecule therapeutics. The companies declined to disclose financial terms. PhoreMost Ltd....
BioCentury | May 4, 2015
Company News

Phylogica, PhoreMost deal

...Phylogica granted PhoreMost non-exclusive, worldwide rights to use undisclosed Phylomer libraries to screen cancer targets and...
...stake in PhoreMost. The companies declined to provide further terms. Phylogica Ltd. (ASX:PYC;Xetra:PH7), Subiaco, Australia PhoreMost Ltd....
BioCentury | Apr 13, 2015
Financial News

PhoreMost completes venture financing

PhoreMost Ltd. , Cambridge, U.K. Business: Cancer Date completed: 2015-04-07 Type: Venture financing Raised: L2.5 million ($3.7 million) Investors: Cambridge Angels; Amadeus Capital Partners; o2h Ventures; Cambridge Enterprise; company management WIR Staff...
Items per page:
1 - 10 of 10